Systemic Lupus Erythematosus Clinical Trials

206 recruitingLast updated: June 17, 2026

There are 206 actively recruiting systemic lupus erythematosus clinical trials across 62 countries. Studies span Phase 1, Phase 2, Not Applicable, Early Phase 1, Phase 3, Phase 4. Top locations include Beijing, Beijing Municipality, China, New York, New York, United States, Beijing, China. Updated daily from ClinicalTrials.gov.


Systemic Lupus Erythematosus Trials at a Glance

206 actively recruiting trials for systemic lupus erythematosus are listed on ClinicalTrialsFinder across 6 cities in 62 countries. The largest study group is Phase 1 with 83 trials, with the heaviest enrollment activity in Beijing, New York, and Beijing. Lead sponsors running systemic lupus erythematosus studies include AstraZeneca, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, and China Immunotech (Beijing) Biotechnology Co., Ltd..

Browse systemic lupus erythematosus trials by phase

Treatments under study

About Systemic Lupus Erythematosus Clinical Trials

Looking for clinical trials for Systemic Lupus Erythematosus? There are currently 136 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Systemic Lupus Erythematosus trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Systemic Lupus Erythematosus clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 206 trials

Recruiting
Phase 1

A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)

Rheumatoid ArthritisSystemic Lupus Erythematosus
AbbVie30 enrolled6 locationsNCT07607964
Recruiting

Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires

Systemic Lupus Erythematosus (SLE)Primary Ovarian Insufficiency (Poi)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)100 enrolled1 locationNCT05567198
Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

Systemic Lupus Erythematosus
UCB Biopharma SRL450 enrolled230 locationsNCT06617325
Recruiting
Phase 1Phase 2

CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus

CAR-T CellSLESystemic Lupus Erythematosus (SLE)+4 more
Children's Hospital of Philadelphia24 enrolled1 locationNCT06839976
Recruiting
Phase 1

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

Malignant Solid NeoplasmHematopoietic and Lymphoid Cell NeoplasmRheumatoid Arthritis+11 more
National Cancer Institute (NCI)300 enrolled52 locationsNCT03816345
Recruiting
Phase 1

NK010 or NK042 in Combination With Rituximab for Refractory Systemic Lupus Erythematosus/Lupus Nephritis

Refractory Lupus NephritisRefractory Systemic Lupus Erythematosus
Guangdong Provincial People's Hospital18 enrolled1 locationNCT06676631
Recruiting

A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants

Systemic Lupus Erythematosus (SLE)
Bristol-Myers Squibb223 enrolled64 locationsNCT07175285
Recruiting
Phase 2

A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus
Boehringer Ingelheim405 enrolled139 locationsNCT07409181
Recruiting
Phase 1

US Zamto-cel Autoimmune Diseases

Systemic Lupus ErythematosusDiffuse Cutaneous Systemic SclerosisSystemic Sclerosis (SSc)+1 more
Miltenyi Biomedicine GmbH48 enrolled1 locationNCT06708845
Recruiting
Phase 1

A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)

Rheumatoid ArthritisSystemic Lupus Erythematosus
Merck Sharp & Dohme LLC21 enrolled15 locationsNCT07363590
Recruiting

Reduced Vaccine Response to HZ/su in SLE

Systemic Lupus ErythematosusZosterVaccine Reaction
Seoul National University Hospital80 enrolled1 locationNCT07636044
Recruiting
Phase 2

A Study of E6742 in Participants With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus
Eisai Co., Ltd.256 enrolled22 locationsNCT07515014
Recruiting

EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases

PericarditisRheumatoid ArthritisSarcoidosis+10 more
Assistance Publique - Hôpitaux de Paris5,000 enrolled1 locationNCT07077304
Recruiting
Phase 1

A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)

Rheumatoid ArthritisHealthySystemic Lupus Erythematosus
Eli Lilly and Company63 enrolled1 locationNCT07276958
Recruiting
Phase 1Phase 2

Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus

Systemic Lupus Erythematosus (SLE)
National Heart, Lung, and Blood Institute (NHLBI)78 enrolled1 locationNCT06032923
Recruiting
Phase 1

A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)

Rheumatoid ArthritisSystemic Lupus ErythematosusSystemic Sclerosis+1 more
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company270 enrolled54 locationsNCT05869955
Recruiting
Phase 4

A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus
GlaxoSmithKline350 enrolled114 locationsNCT06411249
Recruiting
Early Phase 1

Evaluation of Safety, Pharmacokinetics and Pharmacodynamics of Arnovie101, an mRNA-LNP-Based In Vivo CAR-T Therapy, for the Treatment of B Cell-Mediated Autoimmune Diseases (SLE and AIHA)

Systemic Lupus ErythematosusAutoimmune Hemolytic Anemia, AIHA
Circunited BioPharma (Shenzhen) Co., Ltd.5 enrolled1 locationNCT07629596
Recruiting
Phase 3

A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus

Systemic Lupus Erythematosus
AstraZeneca245 enrolled79 locationsNCT07430306
Recruiting
Phase 1Phase 2

A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE/CLE Participants

Systemic Lupus Erythematosus (SLE) or Cutaneous Lupus Erythematosus
DualityBio Inc.148 enrolled7 locationsNCT06625671